BioRestorative Therapies, Inc.

NasdaqCM:BRTX Stock Report

Market Cap: US$9.7m

BioRestorative Therapies Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Lance Alstodt

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage38.2%
CEO tenure4yrs
CEO ownership2.5%
Management average tenure4yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

BioRestorative begins enrollment in mid-stage study of stem cell therapy for lumbar disk disease

Jun 30

CEO Compensation Analysis

How has Lance Alstodt's remuneration changed compared to BioRestorative Therapies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$2m

Jun 30 2024n/an/a

-US$4m

Mar 31 2024n/an/a

-US$5m

Dec 31 2023US$1mUS$479k

-US$10m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$17m

Mar 31 2023n/an/a

-US$16m

Dec 31 2022US$452kUS$400k

-US$13m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$34m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$21mUS$275k

-US$44m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$64kUS$64k

-US$11m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$11m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$350kUS$350k

-US$15m

Sep 30 2019n/an/a

-US$17m

Jun 30 2019n/an/a

-US$15m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$750kUS$73k

-US$13m

Compensation vs Market: Lance's total compensation ($USD1.25M) is above average for companies of similar size in the US market ($USD653.78K).

Compensation vs Earnings: Lance's compensation has increased whilst the company is unprofitable.

CEO

Lance Alstodt (53 yo)

4yrs

Tenure

US$1,254,167

Compensation

Mr. Lance Alstodt serves as President, Chief Executive Officer and Chairman of the Board at BioRestorative Therapies, Inc. since November 16, 2020 and also served as Executive Vice President & Chief Strate...

Leadership Team

NamePositionTenureCompensationOwnership
Lance Alstodt
Chairman of the Board4yrsUS$1.25m2.48%
$ 240.6k
Robert Kristal
Chief Financial Officer3yrsUS$618.12k0.12%
$ 11.2k
Francisco Silva
Chief Scientist4yrsUS$1.20m2.43%
$ 235.1k
Stephen Kilmer
Investor Relations Officerno datano datano data
Robert Paccasassi
Vice President of Quality Assurance & Regulatory Compliance9.2yrsUS$287.85kno data
Wayne Olan
Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board6.5yrsno datano data

4.0yrs

Average Tenure

54yo

Average Age

Experienced Management: BRTX's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Lance Alstodt
Chairman of the Board4yrsUS$1.25m2.48%
$ 240.6k
Francisco Silva
Chief Scientist4yrsUS$1.20m2.43%
$ 235.1k
Wayne Olan
Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board10.6yrsno datano data
Wayne Marasco
Chairman of Scientific Advisory Board12.2yrsno datano data
Joy Cavagnaro
Member of Scientific Advisory Board9.8yrsno datano data
Harvinder Sandhu
Member of Scientific Advisory Board6.1yrsno datano data
Patrick Williams
Independent Director3yrsUS$120.00k0%
$ 0
David Rosa
Independent Director3yrsUS$120.00k0%
$ 0
Nickolay Kukekov
Independent Director3.7yrsUS$120.00k0%
$ 0
Jason Lipetz
Member of Scientific Advisory Board6.3yrsno datano data
Christopher Plastaras
Member of Scientific Advisory Board6.1yrsno datano data

6.1yrs

Average Tenure

52yo

Average Age

Experienced Board: BRTX's board of directors are considered experienced (6.1 years average tenure).